Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 9/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.60 |
| ▸ | CLK4 | Q9HAZ1 | 6/20 | 0.60 |
| ▸ | PIP4K2A | P48426 | 2/20 | 0.60 |
| ▸ | PIP4K2B | P78356 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.56 |
| ▸ | TSHR | P16473 | 5/20 | 0.56 |
| ▸ | USP2 | O75604 | 5/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4200935 | 0.90 | PIP4K2A (0.58) | CYP1A2CYP3A4CYP2D6CLK4PIP4K2A | |
| SCHEMBL2822751 | 0.87 | PIP4K2A (0.56) | CYP1A2CYP3A4CYP2D6CLK4PIP4K2A | |
| SCHEMBL4191762 | 0.87 | PIP4K2A (0.59) | CYP1A2CYP3A4CYP2D6CLK4PIP4K2A | |
| SCHEMBL4196450 | 0.87 | PIP4K2A (0.58) | CYP1A2CYP3A4CYP2D6CLK4PIP4K2A | |
| SCHEMBL4194464 | 0.86 | PIP4K2A (0.55) | CYP1A2CYP3A4CYP2D6CLK4PIP4K2A | |
| SCHEMBL4187496 | 0.83 | FYN (0.69) | PIP4K2APIP4K2BJAK2PTK2 | |
| SCHEMBL4193397 | 0.83 | PIP4K2A (0.54) | CYP1A2CYP3A4CYP2D6CLK4PIP4K2A | |
| SCHEMBL12352764 | 0.83 | CYP11B1 (0.60) | CYP1A2CYP3A4CYP2D6CLK4PIP4K2A | |
| SCHEMBL4195767 | 0.82 | PIP4K2A (0.56) | CYP1A2CYP3A4CYP2D6CLK4PIP4K2A | |
| SCHEMBL21092440 | 0.82 | KIF11 (0.69) | CYP1A2CYP3A4CYP2D6CLK4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090196912-A1 | Pyridinylamines | GPC BOTECH AG (DE) | 2009-08-06 | — | — | US | claimed |
| EP-1789393-A2 | PYRIDINYLAMINES | GPC Biotech AG (DE) | 2007-05-30 | — | — | EP | claimed |
| WO-2006010637-A2 | PYRIDINYLAMINES | GPC BIOTECH AG (DE) | 2006-02-02 | — | — | WO | claimed |
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2020-07-02 | — | — | US | disclosed |
| US-10383847-B2 | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo | BROWN DENNIS M (US) | 2019-08-20 | — | — | US | disclosed |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2016-08-25 | — | — | US | disclosed |
| US-20090196912-A1 | Pyridinylamines | GPC BOTECH AG (DE) | 2009-08-06 | — | — | US | disclosed |
| EP-1789393-A2 | PYRIDINYLAMINES | GPC Biotech AG (DE) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006010637-A2 | PYRIDINYLAMINES | GPC BIOTECH AG (DE) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10383847-B2 | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo | NEK9, NEK7, NEK3 | CYP1A2 349/4885CYP3A4 257/4885CYP2D6 1469/4885 |
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | CYP1A2 349/4885CYP3A4 257/4885CYP2D6 1469/4885 |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | CYP1A2 349/4885CYP3A4 257/4885CYP2D6 1469/4885 |
| US-20090196912-A1 | Pyridinylamines | PRNP, PLPBP, SNCA | CYP1A2 775/4885CYP3A4 328/4885CYP2D6 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.